Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)
Funding Opportunity RFA-CA-24-006 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled Investigation of the Transmission of KSHV (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 16, 2023 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)
Notice NOT-CA-23-067 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 8, 2023 Category: Research Source Type: funding
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-20-046 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and ot...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 23, 2020 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
Notice NOT-CA-20-098 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 2, 2020 Category: Research Source Type: funding
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Funding Opportunity RFA-CA-19-056 from the NIH Guide for Grants and Contracts. The purpose of the proposed Funding Opportunity Announcement (FOA) is to continue support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: 1) Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 11, 2019 Category: Research Source Type: funding
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-18-014 from the NIH Guide for Grants and Contracts. The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of develop...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 10, 2018 Category: Research Source Type: funding
Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-18-013 from the NIH Guide for Grants and Contracts. The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of develop...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 10, 2018 Category: Research Source Type: funding
Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)
Funding Opportunity ID: 291452 Opportunity Number: PA-17-138 Opportunity Title: Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: EducationHealthCategory Explanation: CFDA Number(s): 93.396Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American...
Source: Grants.gov - February 19, 2017 Category: Research Tags: Education Health Source Type: funding
Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)
Funding Opportunity PA-17-138 from the NIH Guide for Grants and Contracts. This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as dr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 26, 2017 Category: Research Source Type: funding
Notice of Change to Budget Instructions for PA-16-252 "Gene Fusions in Pediatric Sarcoma (R21)"
Notice NOT-CA-17-002 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 18, 2016 Category: Research Source Type: funding
Notice of Change to Budget Instructions for PA-16-251 "Gene Fusions in Pediatric Sarcoma (R01)"
Notice NOT-CA-17-003 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 8, 2016 Category: Research Source Type: funding
Gene Fusions in Pediatric Sarcomas (R21)
Funding Opportunity Number: PA-16-252 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.396Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with ...
Source: Grants.gov - May 10, 2016 Category: Research Tags: Education Health Source Type: funding
Gene Fusions in Pediatric Sarcomas (R01)
Funding Opportunity Number: PA-16-251 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: EducationHealthCFDA Number: 93.396Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with ...
Source: Grants.gov - May 10, 2016 Category: Research Tags: Education Health Source Type: funding
Gene Fusions in Pediatric Sarcomas (R01)
Funding Opportunity PA-16-251 from the NIH Guide for Grants and Contracts. The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel thera...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 10, 2016 Category: Research Source Type: funding
